LifeStance Health Group (NASDAQ:LFST) Hits New 1-Year Low at $4.69

LifeStance Health Group, Inc. (NASDAQ:LFST)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $4.69 and last traded at $4.70, with a volume of 709714 shares traded. The stock had previously closed at $4.81.

Analysts Set New Price Targets

Several research analysts have recently issued reports on LFST shares. Barclays raised their target price on shares of LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Thursday, February 29th. Morgan Stanley reaffirmed an “overweight” rating and issued a $10.00 target price on shares of LifeStance Health Group in a research note on Monday, April 22nd. Jefferies Financial Group raised their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, The Goldman Sachs Group lifted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.80.

LifeStance Health Group Stock Performance

The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.20. The stock’s fifty day moving average price is $6.07 and its 200-day moving average price is $6.52.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. LifeStance Health Group had a negative net margin of 15.69% and a negative return on equity of 11.92%. The company had revenue of $300.44 million for the quarter, compared to the consensus estimate of $299.02 million. During the same period last year, the company earned ($0.09) earnings per share. The firm’s revenue was up 18.9% compared to the same quarter last year. On average, analysts predict that LifeStance Health Group, Inc. will post -0.26 EPS for the current fiscal year.

Insider Activity

In other LifeStance Health Group news, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $5.89, for a total transaction of $22,395,812.05. Following the sale, the insider now directly owns 41,932,358 shares of the company’s stock, valued at $246,981,588.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other LifeStance Health Group news, insider Paula Cipollone sold 48,278 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $7.22, for a total transaction of $348,567.16. Following the sale, the insider now directly owns 239,915 shares of the company’s stock, valued at $1,732,186.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $5.89, for a total transaction of $22,395,812.05. Following the sale, the insider now directly owns 41,932,358 shares in the company, valued at $246,981,588.62. The disclosure for this sale can be found here. Insiders have sold 4,100,681 shares of company stock worth $24,087,326 over the last ninety days. Insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its position in shares of LifeStance Health Group by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 744,617 shares of the company’s stock valued at $5,830,000 after purchasing an additional 5,112 shares during the period. Brown Advisory Inc. boosted its stake in shares of LifeStance Health Group by 25.9% in the 4th quarter. Brown Advisory Inc. now owns 5,158,980 shares of the company’s stock valued at $40,395,000 after purchasing an additional 1,062,887 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of LifeStance Health Group by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 4,006,344 shares of the company’s stock valued at $31,370,000 after purchasing an additional 110,457 shares in the last quarter. Assetmark Inc. boosted its stake in shares of LifeStance Health Group by 21.6% in the 4th quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock valued at $93,000 after purchasing an additional 2,114 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of LifeStance Health Group by 37.6% in the 4th quarter. SG Americas Securities LLC now owns 41,325 shares of the company’s stock valued at $324,000 after purchasing an additional 11,295 shares in the last quarter. 85.50% of the stock is owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.